This CME program will highlight recent advances in intensive antiplatelet therapy to improve outcomes in patients with acute coronary syndrome (ACS). The expert faculty, led by Dr. Christopher P. Cannon, will review platelet inhibition science as well as unmet needs in ACS. Following, recent clinical trial data, including outcomes data, will be analyzed and clinical relevance debated in an interactive panel format. Best practices for providing individualized, long-term treatment for patients will be outlined, including the role of aspirin in ACS care. Upon completing this CME activity, learners will be better equipped to treat and manage their patients with acute coronary syndrome.
Cardiologists, internists and other clinicians who manage patients with ACS
I. Platelet Inhibition Science and ACS/PCI Unmet Needs
- The Importance of the P2Y12 Platelet Receptor
- Optimizing Duration of DAPT
II. Review of Antiplatelet Outcomes Trials
III. Newer Antiplatelet Trials
- ISAR-REACT 5
IV. Long-term Treatment, Who and When to Drop Aspirin
V. Trial Analysis Summary
- Review contemporary clinical trial data for intensive antiplatelet therapeutics to improve outcomes for patients with ACS
- Analyze optimal treatment plans for intensive antiplatelet therapy to improve outcomes in patients with ACS
Roxana Mehran, MD
Mount Sinai Professor in Cardiovascular Clinical Research and Outcomes
Director of Interventional Cardiovascular Research and Clinical Trials
Icahn School of Medicine at Mount Sinai
New York, NY
Stephen D. Wiviott, MD
Executive Director Clinical Trials Office, Partners HealthCare
Senior Investigator, TIMI Study Group
Cardiovascular Division, Brigham and Women’s Hospital
Associate Professor of Medicine, Harvard Medical School
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Christopher Cannon; MD
|Consultant/Advisor: Aegerion Pharmaceuticals Inc.; Alnylam Pharmaceuticals Inc.; Amarin Corporation; Amgen Inc.; Applied Therapeutics; Ascendia Pharmaceuticals; BGB Group; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Corvidia Therapeutics; HLS Therapeutics Inc.; Innovent Biologics Inc.; Janssen Pharmaceuticals; Kowa Pharmaceuticals; Inc.; Merck; Pfizer Inc.; Sanofi
Grant/Research Support: Amgen Inc.; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo Inc.; Janssen Pharmaceuticals; Merck; Pfizer Inc.
Deepak L. Bhatt; MD; MPH
|Consultant/Advisor: American Heart Association Quality Oversight Committee; Baim Institute for Clinical Research; Boston VA Research Institute; Cardax Inc.; Cereno Scientific; Cleveland Clinic; Duke Clinical Research Institute; Elsevier Practice Update Cardiology; Mayo Clinic; Mount Sinai School of Population Health Research Institute; Medscape Cardiology; PhaseBio Pharmaceuticals; Inc.; Regado Biosciences; Society of Cardiovascular Patient Care; TobeSoft Co. Ltd.
Grant/Research Support: Abbott Laboratories; Afimmune Limited; Amarin Corporation; Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Chiesi USA Inc.; CSL Behring; Eisai Co. Ltd.; Ethicon Inc.; Ferring Pharmaceuticals; Forest Laboratories; Fractyl Laboratories; Inc.; Idorsia Pharmaceuticals Ltd.; Ironwood Pharmaceuticals; Inc; Ischemix; Eli Lilly & Co.; Medtronic; PhaseBio Pharmaceuticals Inc; Pfizer Inc.; PLx Pharma; Regeneron Pharmaceuticals; Inc.; Roche Pharma; Sanofi Aventis U.S. LLC; Synaptic Pharma Ltd; The Medicines Company
Roxana Mehran, MD
|Consultant/Advisor: Abbott Laboratories; Boston Scientific; Siemens Medical Solutions; Phillips (Spectranetics); PLx Pharma; Roivant Sciences Inc; Volcano Corporation; Sanofi; Janssen Pharmaceuticals
Grant/Research Support: Abbott Laboratories; Astra Zeneca; Bayer; Beth Israel Deaconess; BMS; CSL Behring; DSI; Medtronic; Boston Scientific; Novartis; Orbus Neich
Stephen D. Wiviott; MD
|Consultant/Advisor: ARENA Pharmaceuticals; AstraZeneca Pharmaceuticals; Aegerion Pharmaceuticals; Allergan plc; Angelmed; Boehringer-Ingelheim; Boston Clinical Research Institute; Bristol Myers Squibb Company; Daiichi Sankyo; Eisai Co; Ltd.; Eli Lilly & Co.; Icon Clinical; Janssen Pharmaceuticals; Lexicon Pharmaceuticals. Inc.; Merck; Servier Pharmaceuticals; St Jude Medical; Xoma Corporation
Grant/Research Support: Amgen Inc.; Arena Pharmaceuticals; AstraZeneca Pharmaceuticals; Bristol Myers Squibb Company; Daiichi Sankyo; Inc.; Eisai Co. Ltd.; Eli Lilly & Co.; Janssen Pharmaceuticals; Merck; Sanofi-Aventis U.S. LLC
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 1.5 AMA PRA Category 1 CreditsTM.
This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and from AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].